DRI Healthcare Trust Price Target Cut to C$16.00/Share From C$20.00 by RBC Capital
DRI Healthcare Trust Price Target Cut to C$16.00/Share From C$20.00 by RBC
DRI Healthcare Trust Price Target Cut to C$15.00/Share From C$22.00 by Stifel Nicolaus
DRI Healthcare Trust Price Target Cut to C$15.00/Share From C$22.00 by Stifel
DRI Healthcare Trust Is Maintained at Outperform by National Bank
DRI Healthcare Trust Is Maintained at Outperform by National
DRI Healthcare Trust Downgraded to Hold as CEO Fired Amid an Investigation; Price Target Cut to C$15.00
Stifel GMP on Tuesday downgraded its rating on the units of DRI Healthcare Trust (DHT-UN.TO) to hold from buy, while cutting its price target to C$15.00 from C$22.00 after the company's chief
DRI Healthcare Price Target Lowered to $18.50 at CIBC
CIBC Capital Markets lowered its price target on DRI Healthcare Trust (DHT-U.TO) to $18.50 from $20.Analyst Scott Fletcher maintained an Outperformer rating on shares of the Toronto-based healthcare
Express News | RBC Capital Maintains Outperform on DRI HEALTHCARE TRUST, Lowers Price Target to C$16
National Bank on DRI Healthcare Trust's CEO Departure Over Certain Expense "Irregularities"
DRI Healthcare demanded Behzad Khosrowshahi's resignation as a result of an ongoing investigation of irregularities related to certain alleged consulting and other expenses he presented for reimbursem
Toronto Stocks Slip, DRI Healthcare Shares Fall on Ex-CEO Investigation, New Appointments
Toronto-listed stocks were slightly lower Monday. The biggest losses were in the materials sector, followed by energy and transportation.
DRI Healthcare Trust, DRI Capital Report Executive Changes Amid Probe of Irregularities
DRI Healthcare Trust (DHT-UN.TO) said on Monday that its board of trustees demanded and received the immediate resignation of Behzad Khosrowshahi from the board and as CEO of the Trust.Khosrowshahi al
DRI Healthcare Trust Shuffles Board Amid Investigation Into Former CEO's Expenses
By Adriano Marchese DRI Healthcare Trust has appointed a new interim head of the company and the managing company of the trust amid an investigation into its former chief executive on potential expens
Truist Securities on DRI Healthcare Trust's Xenpozyme Royalty Add-on
DRI Healthcare Trust's US$46 million acquisition (US$13 million upfront + US$33 million in milestones) of royalty on Xenpozyme adds incremental 1% royalty on global sales to the trust's current 1% str
DRI Healthcare Trust to Host Second Quarter Earnings Call and Webcast on August 7, 2024
National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition
DRI Healthcare Trust acquired a second royalty stream in Xenpozyme from HLS Therapeutics, notes National Bank. This investment is DHT's second royalty stream on Xenpozyme, with the first US$30 million
DRI Healthcare Trust Boosts Rare Disease Portfolio
Express News | RBC Capital Reiterates Outperform on DRI HEALTHCARE TRUST, Maintains C$20 Price Target
DRI Healthcare Trust Price Target Raised to C$20.00/Share From C$19.50 by CIBC World Markets
DRI Healthcare Trust Price Target Raised to C$20.00/Share From C$19.50 by CIBC World Markets
DRI Healthcare Trust Price Target Cut to C$19.00/Share From C$19.50 by Canaccord Genuity
DRI Healthcare Trust Price Target Cut to C$19.00/Share From C$19.50 by Canaccord Genuity
DRI Healthcare Trust Is Maintained at Outperform by CIBC World Markets
DRI Healthcare Trust Is Maintained at Outperform by CIBC World Markets
DRI Healthcare Trust Is Maintained at Buy by Canaccord Genuity
DRI Healthcare Trust Is Maintained at Buy by Canaccord Genuity
DRI Healthcare Trust Affirms Leadership at AGM